Novo Nordisk (NVO) Today — Nov. 12, 2025: WeightWatchers to Offer Wegovy Pill, Canada Eyes Ozempic Copies, and the Latest Stock Move
WeightWatchers plans to offer Novo Nordisk’s oral Wegovy in the U.S. after its expected 2026 launch. Sandoz says unbranded Ozempic could reach Canada by June 2026, intensifying price competition. CVS dropped Lilly’s Zepbound from its preferred list, keeping Wegovy, prompting Lilly to move employees off CVS plans. Novo Nordisk shares traded at $49.76 late Wednesday, up slightly.